PREVNAR and PREVNAR 13 are registered trademarks of Wyeth LLC.
Manufactured by Wyeth Pharmaceuticals Inc. © 2015 Pfizer Inc. All rights reserved. June 2015. Marketed by Pfizer Inc.
Based on LAB-0469-12.0 (May 2015)
WHO SHOULD RECEIVE PREVNAR 13®
(Pneumococcal 13-valent Conjugate Vaccine
[Diphtheria CRM197 Protein])?
• Prevnar 13® is approved for adults 50 years and older
for the prevention of pneumococcal pneumonia and
invasive disease caused by the 13 vaccine strains
• Prevnar 13® is a vaccine also approved for children
6 weeks through 17 years of age for the prevention
of invasive disease caused by the 13 strains of
Streptococcus pneumoniae included in the vaccine, and
for children 6 weeks through 5 years for the prevention
of ear infections caused by 7 of the 13 strains
• Prevnar 13® is not 100% effective and will only help
protect against the 13 strains included in the vaccine
Adults 50 years and older:
• A single dose of Prevnar 13® is recommended for adults
aged 50 years of age and older
Children 6 weeks through 5 years of age:
• Prevnar 13® is recommended for children 6 weeks
through 5 years of age
• Prevnar 13® is given as a 4-dose series at 2, 4, 6, and
12 to 15 months of age
• Transition schedule: Children who have received 1
or more doses of Prevnar® (Pneumococcal 7-valent
Conjugate Vaccine [Diphtheria CRM197 Protein]) may
complete the 4-dose immunization series with Prevnar 13®
• Catch-up schedule: Children 15 months through 5 years
of age who are considered fully immunized with Prevnar®
may receive 1 dose of Prevnar 13® to elicit immune
responses to the 6 additional strains
• The immune responses from the transition or catch-up
schedules might be lower for the 6 additional strains
(types 1, 3, 5, 6A, 7F, and 19A) than if your child had
received the full 4 doses of Prevnar 13®
Children 6 years through 17 years of age:
• In children 6 years through 17 years of age, Prevnar 13®
is given as a single dose
WHO SHOULD NOT RECEIVE PREVNAR 13®?
Children or adults who have had a severe allergic reaction
to any component of Prevnar 13® or any diphtheria toxoid–
containing vaccine should not receive Prevnar 13®
WARNING
• A temporary pause of breathing following vaccination
has been observed in some infants born prematurely.
Decisions about when to give Prevnar 13® to infants
born prematurely should be based on consideration of
the individual infant’s medical status, and the potential
benefits and possible risks of vaccination
• The safety and efficacy of Prevnar 13® when given to
persons with a weakened immune system (such as HIV
infection, damaged spleen, cancer, or kidney problems) is
not known. Children or adults with a weakened immune
system may have a reduced response to Prevnar 13®
BEFORE STARTING PREVNAR 13®
Tell your health care provider or your child’s health care
provider about all medical conditions, including:
• Previous allergic reactions to other vaccines
• Especially tell the health care provider if your child or
you are taking medicines that can weaken the immune
system, such as steroids (eg, prednisone) and cancer
medicines, or are undergoing radiation therapy
• If you are pregnant or nursing, or if you plan to become pregnant
WHAT ARE THE POTENTIAL SIDE EFFECTS?
• In adults, the common side effects were pain, redness, or
swelling at the injection site, limitation of arm movement,
fatigue, headache, muscle pain, joint pain, decreased
appetite, chills, or rash
• The most commonly reported serious adverse events
in children were bronchiolitis (an infection of the lungs)
(0.9%), gastroenteritis (inflammation of the stomach and
small intestine) (0.9%), and pneumonia (0.9%)
• In children 6 weeks through 17 years, the most common side
effects were tenderness, redness, or swelling at the injection
site, irritability, decreased appetite, decreased or increased
sleep, and fever. Most commonly reported side effects in
children 5 years through 17 years also included hives
WHAT SHOULD I KNOW ABOUT RECEIVING
PREVNAR 13® WITH OTHER VACCINES?
• In adults, immune responses to Prevnar 13® were
reduced when given with injected seasonal flu vaccine
• When given within 1 year following pneumococcal
polysaccharide vaccine, immune response to Prevnar 13®
may be lower
ADDITIONAL IMPORTANT INFORMATION
• The safety and effectiveness of Prevnar 13® when used
in children less than 6 weeks of age is not known
• In a study in which children received acetaminophen prior to
Prevnar 13®, immune responses to some strains in the vaccine
were lower compared with responses among children who
received acetaminophen after vaccination only as needed
• Ask your health care provider about the risks and benefits
of Prevnar 13®. Only a health care provider can decide if
Prevnar 13® is right for you or your child
NEED MORE INFORMATION?
• This is only a summary of important information. Ask your
health care provider or your child’s health care provider
for complete product information
• Go to www.Prevnar13.com or call 1-800-666-7248
IMPORTANT
FACTS
Prevnar 13® (pronounced “Prev • nar 13”)
Generic Name: Pneumococcal 13-valent
Conjugate Vaccine (Diphtheria CRM197 Protein)
Rx only
WAREHOUSE ONLY | AVAILABLE NOW
